Alnylam Pharmaceuticals, Inc.
(NASDAQ : ALNY)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.19%178.181.3%$463.63m
CELGCelgene Corporation
0.86%97.341.3%$421.72m
GILDGilead Sciences, Inc.
1.27%67.200.9%$393.42m
BIIBBiogen Inc.
2.10%232.441.3%$354.81m
ILMNIllumina, Inc.
0.92%347.183.5%$270.42m
REGNRegeneron Pharmaceuticals, Inc.
1.69%310.412.6%$232.86m
AAgilent Technologies, Inc.
-0.03%69.951.6%$212.01m
VRTXVertex Pharmaceuticals Incorporated
1.57%172.891.9%$197.23m
ARRYArray BioPharma Inc.
55.20%45.938.2%$184.00m
EXASExact Sciences Corporation
0.27%110.0825.3%$183.38m
ALXNAlexion Pharmaceuticals, Inc.
2.40%120.762.0%$176.29m
BMRNBioMarin Pharmaceutical Inc.
4.08%84.144.3%$136.15m
MRTXMirati Therapeutics Inc.
6.23%100.132.5%$113.68m
IONSIonis Pharmaceuticals, Inc.
3.51%64.278.2%$96.36m
INCYIncyte Corporation
4.81%81.452.5%$91.50m

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.